Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy? Time for Another Look

Overview

Journal Hypertension

Date 2007 Apr 25

PMID 17452509

Citations 35

Authors

Timothy L Reudelhuber

Kenneth E Bernstein

Patrick Delafontaine

Affiliations

Soon will be listed here.

Citing Articles

Identification of immune-related genes and small-molecule drugs in hypertension-induced left ventricular hypertrophy based on machine learning algorithms and molecular docking.

Zhou M, Li T, Lv S, Gan W, Zhang F, Che Y Front Immunol. 2024; 15:1351945.

PMID: 38994368 PMC: 11236603. DOI: 10.3389/fimmu.2024.1351945.

Central role for BRAF in cardiac hypertrophy: rethinking the pathological-physiological divide.

Altara R, Booz G Clin Sci (Lond). 2023; 137(2):143-148.

PMID: 36651286 PMC: 9873497. DOI: 10.1042/CS20220776.

Oridonin Relieves Angiotensin II-Induced Cardiac Remodeling via Inhibiting GSDMD-Mediated Inflammation.

Lin S, Dai S, Lin J, Liang X, Wang W, Huang W Cardiovasc Ther. 2022; 2022:3167959.

PMID: 35360548 PMC: 8938085. DOI: 10.1155/2022/3167959.

The Mechanism of High-Output Cardiac Hypertrophy Arising From Potassium Channel Gain-of-Function in Cantú Syndrome.

McClenaghan C, Huang Y, Matkovich S, Kovacs A, Weinheimer C, Perez R Function (Oxf). 2020; 1(1):zqaa004.

PMID: 32865539 PMC: 7446247. DOI: 10.1093/function/zqaa004.

Telmisartan improves myocardial remodeling by inhibiting leptin autocrine activity and activating PPARγ.

Chen H, Li M, Liu L, Zhu D, Tian G Exp Biol Med (Maywood). 2020; 245(7):654-666.

PMID: 32075431 PMC: 7153214. DOI: 10.1177/1535370220908215.

References

Mazzolai L, Nussberger J, Aubert J, Brunner D, Gabbiani G, Brunner H . Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension. 1998; 31(6):1324-30. DOI: 10.1161/01.hyp.31.6.1324. View

Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M . Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995; 95(1):46-54. PMC: 295367. DOI: 10.1172/JCI117675. View

Tokita Y, Franco-Saenz R, Reimann E, Mulrow P . Hypertension in the transgenic rat TGR(mRen-2)27 may be due to enhanced kinetics of the reaction between mouse renin and rat angiotensinogen. Hypertension. 1994; 23(4):422-7. DOI: 10.1161/01.hyp.23.4.422. View

Kimura S, Mullins J, Bunnemann B, Metzger R, Hilgenfeldt U, Zimmermann F . High blood pressure in transgenic mice carrying the rat angiotensinogen gene. EMBO J. 1992; 11(3):821-7. PMC: 556521. DOI: 10.1002/j.1460-2075.1992.tb05119.x. View

Subramaniam A, Jones W, Gulick J, Wert S, Neumann J, Robbins J . Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 1991; 266(36):24613-20. View

Gray M, Long C, Kalinyak J, Li H, Karliner J . Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res. 1999; 40(2):352-63. DOI: 10.1016/s0008-6363(98)00121-7. View

Devereux R, Wachtell K, Gerdts E, Boman K, Nieminen M, Papademetriou V . Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004; 292(19):2350-6. DOI: 10.1001/jama.292.19.2350. View

Wachtell K, Lehto M, Gerdts E, Olsen M, Hornestam B, Dahlof B . Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005; 45(5):712-9. DOI: 10.1016/j.jacc.2004.10.068. View

Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie T, Chen J . Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med. 2001; 7(11):1236-40. DOI: 10.1038/nm1101-1236. View

10.

van Kats J, Methot D, Paradis P, Silversides D, Reudelhuber T . Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice. Direct and indirect effects of angiotensin II on the heart. J Biol Chem. 2001; 276(47):44012-7. DOI: 10.1074/jbc.M106132200. View

11.

Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J . Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001; 38(6):E28-32. DOI: 10.1161/hy1101.099502. View

12.

Thomas W, Brandenburger Y, Autelitano D, Pham T, Qian H, Hannan R . Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res. 2002; 90(2):135-42. DOI: 10.1161/hh0202.104109. View

13.

Mancia G, Carugo S, Grassi G, Lanzarotti A, Schiavina R, Cesana G . Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension. 2002; 39(3):744-9. DOI: 10.1161/hy0302.104669. View

14.

Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

15.

A Crackower M, Sarao R, Oudit G, Yagil C, Kozieradzki I, Scanga S . Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417(6891):822-8. DOI: 10.1038/nature00786. View

16.

Kjeldsen S, Dahlof B, Devereux R, Julius S, Aurup P, Edelman J . Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002; 288(12):1491-8. DOI: 10.1001/jama.288.12.1491. View

17.

. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981-97. DOI: 10.1001/jama.288.23.2981. View

18.

Wing L, Reid C, Ryan P, Beilin L, Brown M, Jennings G . A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348(7):583-92. DOI: 10.1056/NEJMoa021716. View

19.

Sanbe A, Gulick J, Hanks M, Liang Q, Osinska H, Robbins J . Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res. 2003; 92(6):609-16. DOI: 10.1161/01.RES.0000065442.64694.9F. View

20.

Taylor R . Conundrum of the HOPE study: time of taking ramipril may account for lack of relation between blood pressure and outcome. BMJ. 2003; 327(7416):681-2. PMC: 196432. DOI: 10.1136/bmj.327.7416.681-c. View